

PATENT

Attorney Docket No.: INL-044C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Rosén et al.

SERIAL NO.:

10/050,441

GROUP NO.:

1651

FILING DATE:

January 16, 2002

EXAMINER:

Ralph J. Gitomer

TITLE:

IN VITRO METHODS FOR SCREENING FOR BLOOD

COAGULATION DISORDERS USING METAL IONS

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patent application and publication listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patent application and publication are enclosed.

Reference A6 (U.S.S.N. 10/331,731) is related to the above-identified patent application and is presented for consideration by the Examiner.

03/18/2003 BSAYASI1 00000018 10050441

02 FC:1806

180.00 OP

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

		•
	(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
\boxtimes	(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
		the requisite Statement is below, OR
	\boxtimes	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or

MAR 2 0 2003 HOLLING TECH CENTER 1600/2900

	(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
		the requisite Statement is below, AND
		the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.
It is re	spectfu ther inf	Illy requested that each of the patents and publications listed on the attached Form PTO- formation contained herein, be made of record in this application.
		STATEMENT
As req	uired u	nder 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that
[check the a	approp	riate space only if either (2) or (3) is checked on the previous page and the Statement
is required]	 :	
	1.	Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
	2.	No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: March **[0]**, 2003 Reg. No.: 45,508

Tel. No.: (617) 248-7226 Fax No.: (617) 248-7100

2552220

Respectfully submitted,

Daniel A. Wilson Attorney for Applicants

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110